Editas Medicine (EDIT) closed at $2.42 on Oct 19, 2026, up 3.0% on the day. The stock is down 10.4% over the past month, down 16.3% over three months, up 18.0% year to date and down 38.9% over the past year. It trades 43.4% below its 52-week high of $4.28 and 45.8% above its 52-week low of $1.66. The close sits below its 50-day moving average ($2.81) and below its 200-day moving average ($2.66).
NextPick tracks EDIT in its Cell / Gene Therapy basket alongside CRSP, BEAM, VCEL, NTLA and PRME. As of Oct 19, 2026, the basket's money-flow score is -18 (weak outflow), and the basket is down 4.8% over five sessions. Over the past month EDIT ranks 5th of 7 basket members by price change.
No — the Oct 19, 2026 close of $2.42 is 9.0% below the 200-day average of $2.66.
EDIT closed 43.4% below its 52-week high of $4.28.
NextPick groups EDIT with CRSP, BEAM, VCEL, NTLA and PRME in its Cell / Gene Therapy basket.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
